

**Congress of the United States**  
**Washington, DC 20515**

December 10, 2019

The Honorable Nancy P. Pelosi  
Speaker of the House  
H-232, U.S. Capitol  
Washington, DC 20515

Dear Speaker Pelosi:

We understand you plan to bring the partisan drug price control bill, H.R. 3, to the House floor this week for a vote. We request that the rule for H.R. 3 allow for a vote on a substitute.

The American people want action to lower the cost of prescription drugs. They do not want partisan bickering and messaging bills that go nowhere. Unfortunately, H.R. 3 started and remained throughout the year a partisan exercise designed to appease a particular wing of your party. Almost the entirety of 2019 was spent with House Democrat leadership negotiating with the progressive caucus over the design of H.R. 3. At no time did House Democrat leadership ever reach out to House Republicans to try and work together on this legislation. As a result, the legislation does not represent bipartisan input and has no chance of becoming law.


House Republicans, however, do not believe it is enough to simply raise the well-founded and documented concerns with H.R. 3. We believe the American people deserve a comprehensive, bipartisan alternative that has a real chance to become law. Yesterday, House Republicans unveiled H.R. 19, the Lower Costs, More Cures Act. The bill:

- Lowers the cost of prescription drugs by promoting more low-cost options for patients and curbing the gaming of the system by drug companies, all the while encouraging innovation of groundbreaking new cures;
- For the first time ever, places a cap on seniors' out-of-pocket drug costs and allows seniors to manage their annual out-of-pocket spending;
- Makes insulin more affordable;
- Increases transparency and removes uncertainty at the pharmacy counter;
- Cuts the cost of drug administration, including cancer treatment, for Medicare beneficiaries by as much as half;
- Stops subsidizing other developed countries' health care through stronger trade agreements with real enforcement mechanisms.

Equally important, the provisions in H.R. 19 reflect demonstrated bipartisan work. Multiple committees in both the House and Senate have produced bipartisan legislation that address the high cost of drugs. The simple fact that Republicans and Democrats worked together and reported these bills out of committee - at times, with unanimous votes - represents strong evidence that H.R. 19 can become law in 2019.

While the progressive wing of your caucus may be satisfied with a vote only on a partisan price control bill, all Members of the House deserve the opportunity to vote on comprehensive, bipartisan legislation that will reduce drug prices and create more cures. The only bill that accomplishes this goal is H.R. 19. We therefore, respectfully urge you to make the bill in order as a substitute to H.R. 3.

Sincerely,



---

KEVIN McCARTHY  
House Republican Leader



---

STEVE SCALISE  
House Republican Whip



---

LIZ CHENEY  
House Republican Conference Chair

Cc: The Honorable Steny H. Hoyer, Majority Leader  
The Honorable James P. McGovern, Rules Committee Chairman  
The Honorable Tom Cole, Rules Committee Ranking Member